Research Paper Advance Articles pp 24134—24140
Detection of NUCB2/nesfatin-1 in cerebrospinal fluid of multiple sclerosis patients
- 1 Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan
- 2 Department of Neurology, Fukushima Medical University School of Medicine, Fukushima, Japan
- 3 Department of Neurology, Matsumura General Hospital, Fukushima, Japan
Received: October 9, 2020 Accepted: November 16, 2020 Published: December 12, 2020https://doi.org/10.18632/aging.202287
How to Cite
Copyright: © 2020 Shimizu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
NUCB2/nesfatin-1 was originally discovered as an anorexigenic peptide. However, recent studies revealed various additional functions including the regulation of inflammation. However, there are no studies that investigated the involvement of NUCB2/nesfatin-1 in neuroinflammatory diseases. Here, we aimed to investigate the involvement of NUCB2/nesfatin-1 in a representative neuroinflammatory disease, multiple sclerosis (MS).
Cerebrospinal fluids (CSF) were collected from 24 MS patients and 10 control subjects and NUCB2/nesfatin-1, proinflammatory cytokines (TNF-α, IL-1β) and anti-inflammatory cytokines (IL-10, TGF-β) levels were measured by using ELISA assay. Also the expression of NUCB2/nesfatin-1 in the CSF of MS patient was investigated by western blot analysis.
Expression of NUCB2/nesfatin-1 was confirmed in the CSF of the MS patient by western blot analysis. NUCB2/nesfatin-1 levels were significantly higher in the CSF of the MS patients. Among the measured cytokines, only IL-1β was lower in the CSF of the MS patients.
We report for the first time increased NUCB2/nesfatin-1 levels in the CSF of MS patients.